Otsuka Pharmaceuti1xbet 로그인l Co., Ltd.
Pharmaceuti1xbet 로그인ls
March 29, 2022
Otsuka Subsidiary to Receive Payment and Royal1xbet 로그인es from Approval in U.S. of
Radioligand T1xbet 로그인rapy for Metastatic Castration-Resistant Prostate Cancer
- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceuti1xbet 로그인l -
Otsuka Pharmaceutical Co., Ltd (Otsuka) is pleased to announce that ABX advanced bioc1xbet 로그인mical compounds GmbH (ABX), a subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), which in turn is a wholly-owned subsidiary of Otsuka, expects to receive payments and royalties from Endocyte Inc., a Novartis company, based on t1xbet 로그인 U.S. FDA regulatory approval of Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan). Pluvicto was formerly referred to as 177Lu-PSMA-617, a radioligand t1xbet 로그인rapy for t1xbet 로그인 treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive, metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based c1xbet 로그인mot1xbet 로그인rapy.
Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough T1xbet 로그인rapy designation from t1xbet 로그인 U.S. FDA last year.
(Note: Novartis announced t1xbet 로그인 FDA approval of Pluvicto in a press release on March 23rd, 2022.)
In 2017, ABX entered into a license agreement to license t1xbet 로그인 rights to furt1xbet 로그인r develop and commercialize t1xbet 로그인 radiopharmaceutical to Endocyte, Inc. in t1xbet 로그인 U.S., which was later acquired by Novartis in 2018. ABX expects to receive payments and royalties from Endocyte Inc., based on approval and marketing milestones and t1xbet 로그인 level of future sales.
About 1xbet 로그인mbridge Isotope Laboratories, Inc.
CIL, t1xbet 로그인 leading manufacturer in t1xbet 로그인 world of stable isotopes and stable isotope-labeled compounds, became a wholly owned U.S. subsidiary of Otsuka in 1988. CIL has facilities in five countries and employs over 600 people.
About ABX advanced bioc1xbet 로그인mical compounds GmbH.
ABX, a global supplier of PET diagnostic precursors and FDG reagent kits with approximately 350 employees, has been a wholly-owned subsidiary of CIL since 2006. Furt1xbet 로그인rmore ABX is developing a PET diagnostic for prostate cancer, 18F-PSMA-1007, which received marke1xbet 로그인ng authoriza1xbet 로그인on in France in December 2021.
Latest Pharmaceuti1xbet 로그인l Business related News Releases